A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia

We derive a model for describing the dynamics of imatinib-treated chronic myelogenous leukemia (CML). This model is a continuous extension of the agent-based CML model of Roeder et al. (Nat. Med. 12(10), 1181–1184, 2006) and of its recent formulation as a system of difference equations (Kim et al. in Bull. Math. Biol. 70(3), 728–744, 2008). The new model is formulated as a system of partial differential equations that describe various stages of differentiation and maturation of normal hematopoietic cells and of leukemic cells.An imatinib treatment is also incorporated into the model. The simulations of the new PDE model are shown to qualitatively agree with the results that were obtained with the discrete-time (difference equation and agent-based) models. At the same time, for a quantitative agreement, it is necessary to adjust the values of certain parameters, such as the rates of imatinib-induced inhibition and degradation.

[1]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  I. Glauche,et al.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.

[3]  Doron Levy,et al.  Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models , 2008, Bulletin of mathematical biology.

[4]  A multiplicity result for a class of superquadratic Hamiltonian systems , 2003 .

[5]  T. Holyoake,et al.  Evolution of bone marrow transplantation--the original immunotherapy. , 2001, Trends in immunology.

[6]  A. Fokas,et al.  Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. , 1991, Cancer research.

[7]  Michael C Mackey,et al.  A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.

[8]  Doron Levy,et al.  Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. , 2005, Journal of theoretical biology.

[9]  Laurent Pujo-Menjouet,et al.  Contribution to the study of periodic chronic myelogenous leukemia. , 2004, Comptes rendus biologies.

[10]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[11]  Brent Neiman,et al.  A Mathematical Model of Chronic Myelogenous Leukemia , 2000 .

[12]  Helen Moore,et al.  A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. , 2004, Journal of theoretical biology.

[13]  SFT Thijsen,et al.  Chronic myeloid leukemia from basics to bedside , 1999, Leukemia.

[14]  Laurent Pujo-Menjouet,et al.  A mathematical model describing cellular division with a proliferating phase duration depending on the maturity of cells. , 2003 .

[15]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[16]  F. Michor,et al.  Mathematical models of targeted cancer therapy , 2006, British Journal of Cancer.

[17]  Ingo Roeder,et al.  Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.

[18]  Doron Levy,et al.  Mini-Transplants for Chronic Myelogenous Leukemia: A Modeling Perspective , 2007 .

[19]  Franziska Michor,et al.  Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.